Abstract
Aim: This study aims to analyze the prognostic value of seven tumor makers and also investigate the response of palliative chemotherapy in advanced NSCLC patients with advanced disease.Methods: Medical records of 278 advanced NSCLC Chinese patients who received six cycles of palliative chemotherapy were retrospectively reviewed under ethical approval (JSCH2019K-011). Univariate and multivariate Cox regression analyses were performed using SPSS 24 to find the clinical value of these tumor markers and to identify the factors that were associated with progression-free survival (PFS), as well as the response to palliative chemotherapy.Results: In baseline characteristic, the high levels of CEA, CA-125, CA-199, AFP, NSE, CYFRA21-1, and CA15-3 were detected in 209 (75.18%), 139 (50.0%), 62 (22.30%), 18 (6.47%), 155 (55.75%), 176 (63.30%), and 180 (64.74%) patients, respectively. Univariate analysis revealed that patients with high vs. normal levels of all tumor markers had an increased risk of poor prognosis. In the multivariable Cox regression model, the patient with (high vs. normal) CYFRA21-1 levels (HR = 1.454, P = 0.009) demonstrated an increased poor PFS. However, patients with (high vs. normal) CA19-9 levels (HR = 0.524, P < 0.0001) and NSE levels (HR = 0.584, P < 0.0001) presented a decreased risk of PFS. Also, patients receiving 3-drugs regimen had better PFS compared to those on 2-drugs regimen (P = 0.043).Conclusions: The high levels of CYFRA21-1 was correlated with a poor prognostic factor of PFS for Advanced NSCLC patients. However, the high levels of CA19-9 and NSE were associated with a better prognostic factor of PFS. Additionally, smoking habits and tumor status had a poor prognostic factor of PFS. Moreover, we found that antiangiogenic therapy has high efficacy with first-line chemotherapy and longer PFS of NSCLC patients.
Highlights
Lung cancer is one of the most common and fatal cancers worldwide [1, 2]
We evaluated the response to therapy in patients receiving the two forms of palliative chemotherapy (i.e., 2-drugs or 3-drugs regiment)
This retrospective study is one of the few studies that assess the clinical utility of tumor markers CEA, CA19-9, CA125, AFP, NSE, CA15-3, and CYFRA21-1 for prognostic specification as well as for measuring the response to chemotherapy
Summary
Lung cancer is one of the most common and fatal cancers worldwide [1, 2]. Lung cancer is a heterogeneous disease comprising mainly non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), which approximately accounted for 85% and 10–15% of all lung cancer cases respectively [2, 3]. NSCLC survival rate was estimated at 16.8% for men and 25.1% for women in 2012–2015, which are relatively low compared to other cancers [5] This can be explaining by the fact that about two-thirds of NSCLC patients are usually at an advanced stage (i.e., unresectable stage IIIB and IV) at the time of diagnosis [1, 2]. Most of these advanced tumors are not surgically resectable as a result of disseminated (multiple sites) metastatic disease or metastatic sites that are not amenable to surgery. First-line chemotherapy used in most of the advanced NSCLC cases
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
